2L4G
 
 | |
2JRD
 | |
2DCI
 | |
1N03
 | | Model for Active RecA Filament | | Descriptor: | ADENOSINE-5'-DIPHOSPHATE, RecA protein | | Authors: | VanLoock, M.S, Yu, X, Yang, S, Lai, A.L, Low, C, Campbell, M.J, Egelman, E.H. | | Deposit date: | 2002-10-10 | | Release date: | 2003-02-25 | | Last modified: | 2024-02-14 | | Method: | ELECTRON MICROSCOPY (20 Å) | | Cite: | ATP-Mediated Conformational Changes in the RecA Filament
Structure, 11, 2003
|
|
1XOP
 | | NMR structure of G1V mutant of influenza hemagglutinin fusion peptide in DPC micelles at pH 5 | | Descriptor: | Hemagglutinin | | Authors: | Li, Y, Han, X, Lai, A.L, Bushweller, J.H, Cafiso, D.S, Tamm, L.K. | | Deposit date: | 2004-10-06 | | Release date: | 2005-09-27 | | Last modified: | 2024-05-22 | | Method: | SOLUTION NMR | | Cite: | Membrane structures of the hemifusion-inducing fusion peptide mutant G1S and the fusion-blocking mutant G1V of influenza virus hemagglutinin suggest a mechanism for pore opening in membrane fusion.
J.Virol., 79, 2005
|
|
1XOO
 | | NMR structure of G1S mutant of influenza hemagglutinin fusion peptide in DPC micelles at pH 5 | | Descriptor: | Hemagglutinin | | Authors: | Li, Y, Han, X, Lai, A.L, Bushweller, J.H, Cafiso, D.S, Tamm, L.K. | | Deposit date: | 2004-10-06 | | Release date: | 2005-09-27 | | Last modified: | 2024-05-22 | | Method: | SOLUTION NMR | | Cite: | Membrane structures of the hemifusion-inducing fusion peptide mutant G1S and the fusion-blocking mutant G1V of influenza virus hemagglutinin suggest a mechanism for pore opening in membrane fusion.
J.Virol., 79, 2005
|
|
7OLX
 | | MerTK kinase domain with type 1.5 inhibitor containing a tri-methyl pyrazole group | | Descriptor: | CHLORIDE ION, Tyrosine-protein kinase Mer, ~{N}-[[3-[4-[(dimethylamino)methyl]phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]-~{N}-methyl-5-[3-methyl-5-(1,3,5-trimethylpyrazol-4-yl)pyridin-2-yl]-1,3,4-oxadiazol-2-amine | | Authors: | Pflug, A, Schimpl, M, McCoull, W, Nissink, J.W.M, Winter-Holt, J. | | Deposit date: | 2021-05-20 | | Release date: | 2021-09-15 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (1.98 Å) | | Cite: | Optimization of an Imidazo[1,2- a ]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.
J.Med.Chem., 64, 2021
|
|
7OLV
 | | MerTK kinase domain with type 1.5 inhibitor containing a di-methyl, cyano pyrazole group | | Descriptor: | 4-[4-[5-[imidazo[1,2-a]pyridin-6-ylmethyl(methyl)amino]-1,3,4-oxadiazol-2-yl]-3-methyl-phenyl]-2,5-dimethyl-pyrazole-3-carbonitrile, CHLORIDE ION, DIMETHYL SULFOXIDE, ... | | Authors: | Pflug, A, Schimpl, M, McCoull, W, Nissink, J.W.M, Winter-Holt, J. | | Deposit date: | 2021-05-20 | | Release date: | 2021-09-15 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (2.13 Å) | | Cite: | Optimization of an Imidazo[1,2- a ]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.
J.Med.Chem., 64, 2021
|
|
7OLS
 | | MerTK kinase domain with type 1.5 inhibitor containing a di-methyl pyrazole group | | Descriptor: | 5-[4-(1,5-dimethylpyrazol-4-yl)-2-methyl-phenyl]-~{N}-(imidazo[1,2-a]pyridin-6-ylmethyl)-~{N}-methyl-1,3,4-oxadiazol-2-amine, CHLORIDE ION, DIMETHYL SULFOXIDE, ... | | Authors: | Pflug, A, Schimpl, M, McCoull, W, Nissink, J.W.M, Winter-Holt, J. | | Deposit date: | 2021-05-20 | | Release date: | 2021-09-15 | | Last modified: | 2024-01-31 | | Method: | X-RAY DIFFRACTION (1.89 Å) | | Cite: | Optimization of an Imidazo[1,2- a ]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.
J.Med.Chem., 64, 2021
|
|
